STRATA Skin Sciences (SSKN) Common Equity (2010 - 2025)

STRATA Skin Sciences has disclosed Common Equity across 16 years of filings, most recently posting $2.9 million for Q4 2025.

• Common Equity for Q4 2025 came in at $2.9 million, down 41.51% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.9 million (down 41.51% YoY), and the FY2025 annual result was $2.9 million, down 41.51% from the prior year.
• Common Equity came in at $2.9 million for Q4 2025 at STRATA Skin Sciences, up from $1.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $26.2 million in Q3 2021 to a low of $532000.0 in Q2 2025.
• The 5-year median for Common Equity is $16.6 million (2023), against an average of $14.9 million.
• Across the five-year window, Common Equity advanced 0.99% in 2021 and tumbled 94.4% in 2025, its largest moves.
• STRATA Skin Sciences' Common Equity stood at $25.4 million in 2021, then retreated by 14.1% to $21.8 million in 2022, then slumped by 41.88% to $12.7 million in 2023, then slumped by 60.81% to $5.0 million in 2024, then tumbled by 41.51% to $2.9 million in 2025.
• The last three Common Equity figures came in at $2.9 million (Q4 2025), $1.3 million (Q3 2025), and $532000.0 (Q2 2025), per Business Quant data.